Skip to main content
SpringerLink
Log in

Kombination von Nutzen für ältere CLL-Patienten

  • Literatur kompakt_Leukämien und Lymphome
  • Published:
Im Focus Onkologie Aims and scope

In vielen Ländern gilt das Alkylans Chlorambucil als Standardtherapie für CLL-Patienten, die für eine intensivere Therapie nicht geeignet sind. Ein Anti-CD20-Antikörper kann zur Therapieoptimierung beitragen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Hillmen P et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015; 385(9980):1873-83.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Wolfgang Zimmermann

  2. Abteilung für Hämatologie, Onkologie und Stammzelltransplantation, Universitätsklinikum Freiburg, Freiburg, Deutschland

    Rainer Claus

Authors
  1. Wolfgang Zimmermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rainer Claus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rainer Claus.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zimmermann, W., Claus, R. Kombination von Nutzen für ältere CLL-Patienten. Im Focus Onkologie 19, 22–24 (2016). https://doi.org/10.1007/s15015-016-2452-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-016-2452-y

Search

Navigation